Rapid Dose Therapeutics Corp. (DOSE.CN)
CAD 0.19
(2.78%)
CAD 0.19
(2.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.29 Million CAD | 44.78% |
| 2022 | 1.58 Million CAD | 39.02% |
| 2021 | 1.13 Million CAD | -42.73% |
| 2020 | 1.98 Million CAD | 63.1% |
| 2019 | 1.21 Million CAD | 196.26% |
| 2018 | -1.26 Million CAD | -7324.29% |
| 2017 | -17.06 Thousand CAD | -1789.7% |
| 2016 | -903.00 CAD | -140.28% |
| 2015 | 2242.00 CAD | 125.81% |
| 2014 | -8687.00 CAD | -13473.44% |
| 2013 | -64.00 CAD | 99.75% |
| 2012 | -25.94 Thousand CAD | 86.06% |
| 2011 | -186.12 Thousand CAD | 23.05% |
| 2010 | -241.88 Thousand CAD | -209.34% |
| 2009 | -78.19 Thousand CAD | 31.74% |
| 2008 | -114.55 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.53 Million CAD | 3.1% |
| 2024 Q1 | 2.45 Million CAD | 7.28% |
| 2023 Q4 | 2.29 Million CAD | -19.28% |
| 2023 Q3 | 2.84 Million CAD | 20.31% |
| 2023 Q2 | 2.36 Million CAD | 36.45% |
| 2023 Q1 | 1.73 Million CAD | 9.25% |
| 2023 FY | 2.29 Million CAD | 44.78% |
| 2022 Q3 | 1.57 Million CAD | 8.16% |
| 2022 Q4 | 1.58 Million CAD | 0.8% |
| 2022 FY | 1.58 Million CAD | 39.02% |
| 2022 Q1 | 1.09 Million CAD | -4.0% |
| 2022 Q2 | 1.45 Million CAD | 32.83% |
| 2021 Q1 | 842.02 Thousand CAD | -57.66% |
| 2021 Q2 | 786.96 Thousand CAD | -6.54% |
| 2021 Q3 | 1.13 Million CAD | 43.78% |
| 2021 Q4 | 1.13 Million CAD | 0.67% |
| 2021 FY | 1.13 Million CAD | -42.73% |
| 2020 Q2 | 1.36 Million CAD | 28.1% |
| 2020 Q3 | 1.51 Million CAD | 10.77% |
| 2020 Q4 | 1.98 Million CAD | 31.43% |
| 2020 FY | 1.98 Million CAD | 63.1% |
| 2020 Q1 | 1.06 Million CAD | -12.55% |
| 2019 Q4 | 1.21 Million CAD | -3.45% |
| 2019 FY | 1.21 Million CAD | 196.26% |
| 2019 Q1 | -1.12 Million CAD | 10.92% |
| 2019 Q3 | 1.26 Million CAD | 463.59% |
| 2019 Q2 | -347.38 Thousand CAD | 69.22% |
| 2018 Q1 | -668.66 Thousand CAD | -104.94% |
| 2018 FY | -1.26 Million CAD | -7324.29% |
| 2018 Q4 | -1.26 Million CAD | 70.98% |
| 2018 Q3 | -4.36 Million CAD | 27.68% |
| 2018 Q2 | -6.03 Million CAD | -802.8% |
| 2017 FY | -17.06 Thousand CAD | -1789.7% |
| 2017 Q1 | -1429.00 CAD | 75.23% |
| 2017 Q2 | -17.06 Thousand CAD | -1094.12% |
| 2017 Q3 | -1374.00 CAD | 91.95% |
| 2017 Q4 | -326.26 Thousand CAD | -23645.78% |
| 2016 Q2 | -903.00 CAD | -125.96% |
| 2016 Q3 | -31.11 Thousand CAD | -3345.85% |
| 2016 Q4 | -5768.00 CAD | 81.46% |
| 2016 Q1 | 3479.00 CAD | 21.39% |
| 2016 FY | -903.00 CAD | -140.28% |
| 2015 Q2 | 2242.00 CAD | 728.01% |
| 2015 FY | 2242.00 CAD | 125.81% |
| 2015 Q3 | -732.00 CAD | -132.65% |
| 2015 Q4 | 2866.00 CAD | 491.53% |
| 2015 Q1 | -357.00 CAD | -110.4% |
| 2014 Q3 | -6174.00 CAD | 28.93% |
| 2014 Q1 | - CAD | 100.0% |
| 2014 FY | -8687.00 CAD | -13473.44% |
| 2014 Q4 | 3433.00 CAD | 155.6% |
| 2014 Q2 | -8687.00 CAD | 0.0% |
| 2013 Q2 | -64.00 CAD | -8.47% |
| 2013 Q1 | -59.00 CAD | 63.58% |
| 2013 FY | -64.00 CAD | 99.75% |
| 2013 Q4 | -55.00 CAD | 68.39% |
| 2013 Q3 | -174.00 CAD | -171.88% |
| 2012 Q4 | -162.00 CAD | 97.86% |
| 2012 Q1 | -26.57 Thousand CAD | 66.2% |
| 2012 Q2 | -25.94 Thousand CAD | 2.36% |
| 2012 Q3 | -7585.00 CAD | 70.76% |
| 2012 FY | -25.94 Thousand CAD | 86.06% |
| 2011 Q1 | -192.62 Thousand CAD | 5.06% |
| 2011 Q3 | -130.16 Thousand CAD | 30.07% |
| 2011 Q4 | -78.59 Thousand CAD | 39.61% |
| 2011 FY | -186.12 Thousand CAD | 23.05% |
| 2011 Q2 | -186.12 Thousand CAD | 3.37% |
| 2010 Q3 | -235.35 Thousand CAD | 2.7% |
| 2010 FY | -241.88 Thousand CAD | -209.34% |
| 2010 Q2 | -241.88 Thousand CAD | 3.84% |
| 2010 Q1 | -251.55 Thousand CAD | 4.57% |
| 2010 Q4 | -202.89 Thousand CAD | 13.79% |
| 2009 Q3 | -45.86 Thousand CAD | 41.35% |
| 2009 Q4 | -263.58 Thousand CAD | -474.72% |
| 2009 FY | -78.19 Thousand CAD | 31.74% |
| 2009 Q2 | -78.19 Thousand CAD | 0.0% |
| 2008 FY | -114.55 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -125.08 Thousand CAD | 1932.844% |
| Asep Medical Holdings Inc | -44.72 Thousand CAD | 5226.48% |
| BetterLife Pharma Inc. | 207.85 Thousand CAD | -1003.013% |
| BioVaxys Technology Corp. | -977.00 CAD | 234758.444% |
| ChitogenX Inc. | 3.84 Million CAD | 40.297% |
| Defence Therapeutics Inc. | 1.68 Million CAD | -35.666% |
| Entheon Biomedical Corp. | -344.63 Thousand CAD | 765.233% |
| Gemina Laboratories Ltd. | 284.33 Thousand CAD | -706.304% |
| Glow Lifetech Corp. | 116.15 Thousand CAD | -1873.838% |
| Lexston Life Sciences Corp. | -390.4 Thousand CAD | 687.24% |
| Pharmala Biotech Holdings Inc. | 58.49 Thousand CAD | -3819.332% |
| Doseology Sciences Inc. | -1.06 Million CAD | 316.239% |
| MYND Life Sciences Inc. | 2.99 Million CAD | 23.573% |
| Nova Mentis Life Science Corp. | -8088.00 CAD | 28445.858% |
| PharmaTher Holdings Ltd. | -2.13 Million CAD | 207.471% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | 40.183% |
| Telescope Innovations Corp. | -719.49 Thousand CAD | 418.643% |